Olopatadine Hydrochloride Ophthalmic Solution is indicated for the treatment of ocular itching associated with allergic ...

RVL Pharmaceuticals, Inc. and its affiliates (together, "RVL") announces Santen Pharmaceutical Co., Ltd. ("Santen"), a leading ophthalmology company has obtained the manufacturing and marketing ...

Multi-asset pipeline with significant targeted data readouts and milestones -- Two lead ophthalmic gene therapy programs in clinical trials ...

The approval is for its Abbreviated New Drug Application for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). The product is therapeutically equivalent to Alcon Laboratories’ Pataday ...

ST, the barometer index, the S&P BSE Sensex, declined 726.85 points or 0.86% to 84,234.29. The Nifty 50 index dropped 246.40 points or 0.94% to 25,888.10.

Launched VIZZ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025 Achieved approximately $1.6 million in net pr ...

Allotex Inc., a commercial-stage ophthalmic company with active European market adoption, today announced that the U.S. Food and Drug Administration (FDA) has conditionally approved its ...

Gland Pharma has received an approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) filed for Olopatadine Hydrochloride Ophthalmic ...

Track key stock updates, top deals, and performance movers in today's market—see which companies are making headlines now!

Launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product ...

Switching from aflibercept to ranibizumab biosimilars maintains stability in nAMD treatment, offering a cost-effective ...

Okyo Pharma appointed Robert J. Dempsey to serve as the company’s next CEO, according to a press release.